The Food and Drug Administration has approved a meningococcal ABCWY vaccine for use in individuals aged 10 to 25 years, according to a press release from manufacturer GSK. The vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, and Y), which represent the most invasive meningococcal disease cases globally. The vaccine combines antigenic components of the meningococcal group B vaccine and meningococcal groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine. Trial …
Read More